Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones

Andrea Cavazzoni, Mara A. Bonelli, Claudia Fumarola, Silvia La Monica, Kinda Airoud, Ramona Bertoni, Roberta R. Alfieri, Maricla Galetti, Stefano Tramonti, Elena Galvani, Adrian L. Harris, Lesley Ann Martin, Daniele Andreis, Alberto Bottini, Daniele Generali, Pier Giorgio Petronini

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Development of resistance to endocrine therapy is a clinical issue in estrogen receptor (ER)-positive breast cancer. Here we show that persistent activation of AKT/mTOR signaling is crucial to the acquisition of letrozole resistance in cell clones generated from MCF-7/AROM-1 aromatase-expressing breast cancer cells after prolonged letrozole exposure. ERα plays a marginal role in this context. As a proof of concept, the association between PI3K/AKT/mTOR signaling and insensitivity to endocrine therapies was confirmed in breast cancer patients who developed early letrozole resistance in neoadjuvant setting. In addition our results suggest that, regardless of the mechanism mediating the activation of AKT/mTOR pathway, either RAD001 or NVP-BEZ235 treatment may represent a promising strategy to overcome acquired resistance to letrozole in breast cancers dependent on AKT/mTOR signaling.

Original languageEnglish
Pages (from-to)77-87
Number of pages11
JournalCancer Letters
Volume323
Issue number1
DOIs
Publication statusPublished - Oct 1 2012

Fingerprint

letrozole
Phosphatidylinositol 3-Kinases
Clone Cells
Breast Neoplasms
Estrogen Receptors
Aromatase
Therapeutics

Keywords

  • AKT
  • Breast
  • Letrozole
  • MTOR
  • Resistance

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cavazzoni, A., Bonelli, M. A., Fumarola, C., La Monica, S., Airoud, K., Bertoni, R., ... Petronini, P. G. (2012). Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. Cancer Letters, 323(1), 77-87. https://doi.org/10.1016/j.canlet.2012.03.034

Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. / Cavazzoni, Andrea; Bonelli, Mara A.; Fumarola, Claudia; La Monica, Silvia; Airoud, Kinda; Bertoni, Ramona; Alfieri, Roberta R.; Galetti, Maricla; Tramonti, Stefano; Galvani, Elena; Harris, Adrian L.; Martin, Lesley Ann; Andreis, Daniele; Bottini, Alberto; Generali, Daniele; Petronini, Pier Giorgio.

In: Cancer Letters, Vol. 323, No. 1, 01.10.2012, p. 77-87.

Research output: Contribution to journalArticle

Cavazzoni, A, Bonelli, MA, Fumarola, C, La Monica, S, Airoud, K, Bertoni, R, Alfieri, RR, Galetti, M, Tramonti, S, Galvani, E, Harris, AL, Martin, LA, Andreis, D, Bottini, A, Generali, D & Petronini, PG 2012, 'Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones', Cancer Letters, vol. 323, no. 1, pp. 77-87. https://doi.org/10.1016/j.canlet.2012.03.034
Cavazzoni, Andrea ; Bonelli, Mara A. ; Fumarola, Claudia ; La Monica, Silvia ; Airoud, Kinda ; Bertoni, Ramona ; Alfieri, Roberta R. ; Galetti, Maricla ; Tramonti, Stefano ; Galvani, Elena ; Harris, Adrian L. ; Martin, Lesley Ann ; Andreis, Daniele ; Bottini, Alberto ; Generali, Daniele ; Petronini, Pier Giorgio. / Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. In: Cancer Letters. 2012 ; Vol. 323, No. 1. pp. 77-87.
@article{bfcdd04bfaff4fdf945658ca7377b21e,
title = "Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones",
abstract = "Development of resistance to endocrine therapy is a clinical issue in estrogen receptor (ER)-positive breast cancer. Here we show that persistent activation of AKT/mTOR signaling is crucial to the acquisition of letrozole resistance in cell clones generated from MCF-7/AROM-1 aromatase-expressing breast cancer cells after prolonged letrozole exposure. ERα plays a marginal role in this context. As a proof of concept, the association between PI3K/AKT/mTOR signaling and insensitivity to endocrine therapies was confirmed in breast cancer patients who developed early letrozole resistance in neoadjuvant setting. In addition our results suggest that, regardless of the mechanism mediating the activation of AKT/mTOR pathway, either RAD001 or NVP-BEZ235 treatment may represent a promising strategy to overcome acquired resistance to letrozole in breast cancers dependent on AKT/mTOR signaling.",
keywords = "AKT, Breast, Letrozole, MTOR, Resistance",
author = "Andrea Cavazzoni and Bonelli, {Mara A.} and Claudia Fumarola and {La Monica}, Silvia and Kinda Airoud and Ramona Bertoni and Alfieri, {Roberta R.} and Maricla Galetti and Stefano Tramonti and Elena Galvani and Harris, {Adrian L.} and Martin, {Lesley Ann} and Daniele Andreis and Alberto Bottini and Daniele Generali and Petronini, {Pier Giorgio}",
year = "2012",
month = "10",
day = "1",
doi = "10.1016/j.canlet.2012.03.034",
language = "English",
volume = "323",
pages = "77--87",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones

AU - Cavazzoni, Andrea

AU - Bonelli, Mara A.

AU - Fumarola, Claudia

AU - La Monica, Silvia

AU - Airoud, Kinda

AU - Bertoni, Ramona

AU - Alfieri, Roberta R.

AU - Galetti, Maricla

AU - Tramonti, Stefano

AU - Galvani, Elena

AU - Harris, Adrian L.

AU - Martin, Lesley Ann

AU - Andreis, Daniele

AU - Bottini, Alberto

AU - Generali, Daniele

AU - Petronini, Pier Giorgio

PY - 2012/10/1

Y1 - 2012/10/1

N2 - Development of resistance to endocrine therapy is a clinical issue in estrogen receptor (ER)-positive breast cancer. Here we show that persistent activation of AKT/mTOR signaling is crucial to the acquisition of letrozole resistance in cell clones generated from MCF-7/AROM-1 aromatase-expressing breast cancer cells after prolonged letrozole exposure. ERα plays a marginal role in this context. As a proof of concept, the association between PI3K/AKT/mTOR signaling and insensitivity to endocrine therapies was confirmed in breast cancer patients who developed early letrozole resistance in neoadjuvant setting. In addition our results suggest that, regardless of the mechanism mediating the activation of AKT/mTOR pathway, either RAD001 or NVP-BEZ235 treatment may represent a promising strategy to overcome acquired resistance to letrozole in breast cancers dependent on AKT/mTOR signaling.

AB - Development of resistance to endocrine therapy is a clinical issue in estrogen receptor (ER)-positive breast cancer. Here we show that persistent activation of AKT/mTOR signaling is crucial to the acquisition of letrozole resistance in cell clones generated from MCF-7/AROM-1 aromatase-expressing breast cancer cells after prolonged letrozole exposure. ERα plays a marginal role in this context. As a proof of concept, the association between PI3K/AKT/mTOR signaling and insensitivity to endocrine therapies was confirmed in breast cancer patients who developed early letrozole resistance in neoadjuvant setting. In addition our results suggest that, regardless of the mechanism mediating the activation of AKT/mTOR pathway, either RAD001 or NVP-BEZ235 treatment may represent a promising strategy to overcome acquired resistance to letrozole in breast cancers dependent on AKT/mTOR signaling.

KW - AKT

KW - Breast

KW - Letrozole

KW - MTOR

KW - Resistance

UR - http://www.scopus.com/inward/record.url?scp=84861823850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861823850&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2012.03.034

DO - 10.1016/j.canlet.2012.03.034

M3 - Article

VL - 323

SP - 77

EP - 87

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 1

ER -